| WB | 1/500 - 1/2000 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/10000 | Human,Mouse,Rat |
| Aliases | SEMA7A; JMH; SEMAL; CDw108; SEMAK1; H-Sema-L; H-SEMA-K1 |
| Entrez GeneID | 8482 |
| clone | 1D5G8 |
| WB Predicted band size | 74.8kDa |
| Host/Isotype | Mouse IgG1 |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Purified recombinant fragment of human ZAP70 (AA: 169-390) expressed in E. Coli. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide |
+ +
以下是关于CD108抗体的3篇代表性文献及其摘要概括：
1. **文献名称**：*CD108 mediates endothelium-dependent T cell homing and inflammatory response*
**作者**：Smith A, et al.
**摘要**：研究揭示了CD108抗体通过阻断SEMA7A(即CD108蛋白)与整合素β1的相互作用，抑制T细胞向炎症部位的迁移，表明其在调控免疫细胞浸润中的关键作用。
2. **文献名称**：*SEMA7A (CD108) antibody targeting suppresses melanoma progression in vivo*
**作者**：Chen L, et al.
**摘要**：该文献证明抗CD108单克隆抗体通过抑制SEMA7A介导的MAPK信号通路，显著降低黑色素瘤细胞的侵袭和转移，提示其作为肿瘤治疗的潜在靶点。
3. **文献名称**：*CD108 expression correlates with poor prognosis in acute myeloid leukemia*
**作者**：Wang Y, et al.
**摘要**：研究利用CD108抗体进行流式细胞分析，发现AML患者中CD108高表达与化疗耐药性及生存期缩短相关，支持其作为白血病预后标志物的价值。
注：以上文献信息为模拟示例，实际文献需通过PubMed/Google Scholar检索确认。
The CD108 antibody targets the CD108 antigen, also known as SEMA7A (Semaphorin-7A), a member of the semaphorin family involved in axon guidance, immune regulation, and cell migration. SEMA7A is a glycosylphosphatidylinositol (GPI)-anchored glycoprotein expressed on immune cells (e.g., T cells, monocytes), neurons, and certain tumor cells. Structurally, it contains a conserved semaphorin domain, an immunoglobulin-like domain, and a GPI anchor, enabling interactions with receptors like integrins (e.g., β1-integrin) and plexin-C1.
CD108/SEMA7A plays dual roles in immune activation and tissue remodeling. It facilitates T-cell activation, leukocyte migration, and inflammatory responses, while also contributing to neuronal development, angiogenesis, and wound repair. Dysregulation of SEMA7A is linked to autoimmune diseases, neurodegenerative disorders, and cancer progression. For instance, elevated SEMA7A in melanoma promotes metastasis via integrin-mediated signaling.
CD108 antibodies are utilized in research to study these mechanisms through techniques like flow cytometry, immunohistochemistry, and functional blocking assays. Clinically, they hold potential as diagnostic markers or therapeutic agents. For example, anti-SEMA7A monoclonal antibodies are explored for modulating immune responses in autoimmune conditions or inhibiting tumor invasion. Understanding CD108's multifaceted roles continues to drive investigations into its therapeutic applications and pathophysiological significance.
×
